CHA2DS2-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention

被引:7
|
作者
Huang, Xin [1 ]
Zheng, Wen [1 ]
Zhao, Xue Dong [1 ]
Nie, Shao Ping [1 ]
机构
[1] Capital Med Univ, Emergency & Crit Care Ctr, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing, Peoples R China
关键词
CHA(2)DS(2)-VASc score; multivessel disease; percutaneous coronary intervention; slow flow; no-reflow phenomenon; ST elevation myocardial infarction; NO-REFLOW; MICROVASCULAR DYSFUNCTION; HYPERGLYCEMIA; OBSTRUCTION; GUIDELINES; OUTCOMES;
D O I
10.1097/MD.0000000000026162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) have a higher incidence of slow-flow/no-reflow (SF-NR) phenomenon during primary percutaneous coronary intervention (PPCI) than those with single vessel disease. Currently, no effective tools exist to predict the risk of SF-NR in this population. The present study aimed to evaluate whether CHA(2)DS(2)-VASc score can be used as a simple tool to predict this risk. This study consecutively included STEMI patients hospitalized in Beijing Anzhen Hospital from January 2005 to January 2015. Among these patients, 1032 patients with MVD were finally enrolled. Patients were divided into SF-NR (+) group and SF-NR (-) group according to whether SF-NR occurred during PPCI. SF-NR was defined as the thrombolysis in myocardial infarction (TIMI) grade <= 2. There were 134 patients (13%) in the SF-NR (+) group. Compared with the SF-NR (-) group, patients in the SF-NR (+) group are elder, with lower left ventricular ejection fraction and higher CHA(2)DS(2)-VASc score. Multiple logistic regression analysis indicated that CHA(2)DS(2)-VASc score >= 3 (odds ratio [OR], 2.148; 95% confidence interval [CI], 1.389-3.320; P = .001), current smoking (OR, 1.814; 95% CI, 1.19-2.764; P = .006), atrial fibrillation (OR, 2.892; 95% CI, 1.138-7.350; P = .03), complete revascularization (OR, 2.307; 95% CI, 1.202-4.429; P = .01), and total length of stents >= 40 mm (OR, 1.482; 95% CI, 1.011-2.172; P = .04) were independent risk factors of SF-NR. The incidence of SF-NR in patients with CHA(2)DS(2)-VASc score >= 3 was 1.7 times higher than that in patients with CHA(2)DS(2)-VASc score <3. Additionally, patients with CHA(2)DS(2)-VASc score >= 3 plus >= 2 risk factors have 3 times higher incidence of SF-NR than those with CHA(2)DS(2)-VASc score >= 3 plus 0 to 1 risk factor. CHA(2)DS(2)-VASc score >= 3 can be used as a simple and sensitive indicator to predict SF-NR phenomenon and guide the PPCI strategy in STEMI patients with MVD.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The Effects of Intracoronary Tirofiban in Acute ST-segment Elevation Myocardial Infarction Patients with No Reflow and Slow Flow Phenomenon During Primary Percutaneous Coronary Intervention
    Li, C. S.
    Wei, Y. L.
    Pan, J. S.
    CARDIOLOGY, 2009, 114 : 17 - 17
  • [42] Predictors of No-Reflow Phenomenon in Tunisian Patients Undergoing Primary Percutaneous Coronary Intervention for St-Elevation Myocardial Infarction
    Jomaa, Walid
    Jnifene, Zouhair
    Chamtouri, Ikram
    Ben Hamda, Khaldoun
    Maatouk, Faouzi
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (04) : S9 - S9
  • [43] The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Quisi, Alaa
    Alici, Gokhan
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (09)
  • [44] The CHA2DS2VASc score - predictor of hemodynamic complications in patients with ST-segment elevation myocardial infarction
    Scridon, A.
    Serban, R. C.
    Hadadi, L.
    Sus, I.
    Lakatos, E. K.
    Demjen, Z.
    Ceamburu, A.
    Dobreanu, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 591 - 591
  • [45] Study on the predictive ability of emergency CHADS2 score and CHA2DS2-VASc score for coronary artery disease and prognosis in patients with acute ST-segment elevation myocardial infarction
    Huang, Xin
    Lv, Hong
    Liu, Zeyan
    Liu, Yuan
    Yang, Xue
    JOURNAL OF THORACIC DISEASE, 2022, 14 (07) : 2611 - 2620
  • [46] NO-REFLOW PHENOMENON DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION DUE TO MASSIVE CORONARY THROMBOSIS. PATHOGENESIS AND PREDICTORS OF NO-REFLOW
    Zhuravlev, A. S.
    Azarov, A. V.
    Semitko, S. P.
    Ioseliani, D. G.
    KARDIOLOGIYA, 2021, 61 (02) : 99 - 105
  • [47] Long-Term Prognostic Impact of No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With St-Segment Elevation Myocardial Infarction
    Choo, Eunho
    CIRCULATION, 2013, 128 (22)
  • [48] Machine learning prediction of no reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Wang, Lin
    Bao, Pei
    Wang, Xiaochen
    Xu, Banglong
    Liu, Zeyan
    Hu, Guangquan
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2024, 14 (04)
  • [49] Effect of empagliflozin on no-reflow in patients with st elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Nasef, M. A.
    Saber, M.
    Gomaa, Y.
    Kamal, D.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [50] The association of acute-to-chronic glycemic ratio with no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Simsek, Baris
    Cinar, Tufan
    Tanik, Veysel O.
    Inan, Duygu
    Zeren, Gonul
    Avci, Ilhan I.
    Gungor, Baris
    Yilmaz, Fatih
    Tanboga, Ibrahim H.
    Karabay, Can Y.
    KARDIOLOGIA POLSKA, 2021, 79 (02) : 170 - 178